TY - JOUR
T1 - Granulocytes and mast cells in AllergoOncology—Bridging allergy to cancer
T2 - An EAACI position paper
AU - Pascal, Mariona
AU - Bax, Heather J.
AU - Bergmann, Christoph
AU - Bianchini, Rodolfo
AU - Castells, Mariana
AU - Chauhan, Jitesh
AU - De las Vecillas, Leticia
AU - Hartmann, Karin
AU - Álvarez, Elena Izquierdo
AU - Jappe, Uta
AU - Jimenez-Rodriguez, Teodorikez Wilfox
AU - Knol, Edward
AU - Levi-Schaffer, Francesca
AU - Mayorga, Cristobalina
AU - Poli, Aurélie
AU - Redegeld, Frank
AU - Santos, Alexandra F.
AU - Jensen-Jarolim, Erika
AU - Karagiannis, Sophia N.
N1 - FUNDING INFORMATION
SNK has projects supported by the National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC) based at Guy's and St Thomas' NHS Foundation Trust and King's College London (IS-BRC-1215-20006); the Medical Research Council (MR/L023091/1, MR/V049445/1, MR/R015643/1), the Biotechnology and Biological Sciences Research Council (BB/T008709/1); Breast Cancer Now (147; KCL-BCN-Q3); the Cancer Research UK King's Health Partners Centre at King's College London (C604/A25135); The Guy's and St Thomas's Foundation Trust Charity (Melanoma Special Fund, 573); Innovate UK (463087) the British Skin Foundation (006/R/22); Worldwide Cancer Research (24-0087); Cancer Research UK (C30122/A11527; C30122/A15774). SNK has projects supported by the King's Health Partners Centre for Translational Medicine. The views expressed are those of the author(s) and not necessarily those of King's Health Partners. UJ has projects funded by the German Research Foundation (DFG) (JA 1007/2–3), the Federal Ministry of Education and Science (BMBF) (DZL and INDICATE-FH), and the Federal Ministry of Food and Agriculture (BMEL) (AptaSens). MP is employed by Hospital Clínic de Barcelona, Spain, and has projects funded by Instituto Carlos III (ISCIII) and co-funded by the European Union (PI19/00710 and PI22/01469) and RICORS (RD21/0002/0008) from ISCIII co-founded by the European Union. AP is financially supported by the Action Lions Vaincre le Cancer association and by FNRS-Télévie (TLV 2023 RESTAGE). CM has a contract Nicolas Monardes Program (RC0004-2021) and projects PI18/00288 from ISCIII co-funded by the European Regional Development Fund (ERDF) “Una manera de hacer Europa” “Andalucıa se mueve con Europa”, and PI21/00346 and RICORS (RD21/0002/0008) from ISCIII co-founded by the European Union. KH has projects supported by the Swiss National Science Foundation (project no. 310030_207705) and by the EU-H2020-MSCA-COFUND EURIdoc programme (project no. 101034170).
Publisher Copyright:
© 2024 The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
PY - 2024/9
Y1 - 2024/9
N2 - Derived from the myeloid lineage, granulocytes, including basophils, eosinophils, and neutrophils, along with mast cells, play important, often disparate, roles across the allergic disease spectrum. While these cells and their mediators are commonly associated with allergic inflammation, they also exhibit several functions either promoting or restricting tumor growth. In this Position Paper we discuss common granulocyte and mast cell features relating to immunomodulatory functions in allergy and in cancer. We highlight key mechanisms which may inform cancer treatment and propose pertinent areas for future research. We suggest areas where understanding the communication between granulocytes, mast cells, and the tumor microenvironment, will be crucial for identifying immune mechanisms that may be harnessed to counteract tumor development. For example, a comprehensive understanding of allergic and immune factors driving distinct neutrophil states and those mechanisms that link mast cells with immunotherapy resistance, might enable targeted manipulation of specific subpopulations, leading to precision immunotherapy in cancer. We recommend specific areas of investigation in AllergoOncology and knowledge exchange across disease contexts to uncover pertinent reciprocal functions in allergy and cancer and allow therapeutic manipulation of these powerful cell populations. These will help address the unmet needs in stratifying and managing patients with allergic diseases and cancer.
AB - Derived from the myeloid lineage, granulocytes, including basophils, eosinophils, and neutrophils, along with mast cells, play important, often disparate, roles across the allergic disease spectrum. While these cells and their mediators are commonly associated with allergic inflammation, they also exhibit several functions either promoting or restricting tumor growth. In this Position Paper we discuss common granulocyte and mast cell features relating to immunomodulatory functions in allergy and in cancer. We highlight key mechanisms which may inform cancer treatment and propose pertinent areas for future research. We suggest areas where understanding the communication between granulocytes, mast cells, and the tumor microenvironment, will be crucial for identifying immune mechanisms that may be harnessed to counteract tumor development. For example, a comprehensive understanding of allergic and immune factors driving distinct neutrophil states and those mechanisms that link mast cells with immunotherapy resistance, might enable targeted manipulation of specific subpopulations, leading to precision immunotherapy in cancer. We recommend specific areas of investigation in AllergoOncology and knowledge exchange across disease contexts to uncover pertinent reciprocal functions in allergy and cancer and allow therapeutic manipulation of these powerful cell populations. These will help address the unmet needs in stratifying and managing patients with allergic diseases and cancer.
KW - AllergoOncology
KW - allergy
KW - basophils
KW - cancer
KW - eosinophils
KW - granulocytes
KW - mast cells
KW - neutrophils
UR - http://www.scopus.com/inward/record.url?scp=85199101842&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/39036854/
U2 - 10.1111/all.16246
DO - 10.1111/all.16246
M3 - Article
C2 - 39036854
AN - SCOPUS:85199101842
SN - 0105-4538
VL - 79
SP - 2319
EP - 2345
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
IS - 9
ER -